Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-973 in Healthy Adults
NCT06615570Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-973 in pain (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Sep 2024; status: completed.
02
Drugs
VX-973
03
Conditions
pain
Beyond the preview
Go deeper on NCT06615570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615570.